CompanyXENENasdaqBurnaby

Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals develops potassium and sodium channel modulators for neurology and pain.

SEC EDGAR ClinicalTrials.gov xenon-pharma.com

10-QSep 3Latest SEC filing, period to Jun 30

Sep 21Latest story

September 2026

Xenon posts Phase 2 results for XEN1101 in major depressive disorder trial X-NOVA

Sep 21Trial updateazetukalner Xenon Pharmaceuticals Inc.

August 2026

Xenon reports Q2 2026 results, confirms azetukalner NDA submission on track for Q3

Aug 6Clinical readoutazetukalner Xenon Pharmaceuticals Inc.